Participants
Of the 3083 children in the EPIPAGE 2 cohort, 313 were eligible for the EPIREMED trial. The trial’s enrollment consisted of 169 children with a mean (SD) age of 5 years 11 months (2 months), mean (SD) FSIQ score of 88.5 (10.3), and mean (SD) WM score of 80.0 (5.3); 91 children (54%) were female, and 78 (46%) were male. Among these children, 84 were randomized to the intervention group and 85 to the control group. The retention rate at a mean (SD) of 3.0 (1.8) months was 91% and at a mean (SD) of 12.9 (2.6) months was 80% (